| US 7,495,026 B2 | ||
| Neo-tanshinlactone and analogs as potent and selective anti-breast cancer agents | ||
| Kuo-Hsiung Lee, Chapel Hill, N.C. (US); Xihong Wang, Chapel Hill, N.C. (US); Kenneth F. Bastow, Chapel Hill, N.C. (US); and Tian-Shung Wu, Tainan (Taiwan) | ||
| Assigned to The University of North Carolina at Chapel Hill, Chapel Hill, N.C. (US) | ||
| Filed on Mar. 09, 2005, as Appl. No. 11/75,476. | ||
| Claims priority of provisional application 60/552050, filed on Mar. 10, 2004. | ||
| Prior Publication US 2005/0250751 A1, Nov. 10, 2005 | ||
| Int. Cl. A61K 31/366 (2006.01); C07D 493/04 (2006.01) | ||
| U.S. Cl. 514—453 [549/279; 549/276] | 16 Claims |
1. A compound of Formula I:
 R1, R2, R3, R4, R5, R6, R7, R8, and R9 are each independently selected from the group consisting of H, lower alkyl, hydroxy, lower alkoxy, halo, amino, aminoalkyl,
nitro, heteroaryl, aryl, OC(═O)R14, OC(═O)OR14, OC(═O)N(R14)2, O(CH2)mN(R14)2, C(═O)N(R14)2, and O(CH2)mCOOH where m is 1-5 and R14 is H or lower alkyl;
or R1 and R2 together form a covalent bond;
or R2 and R3 together form =Z, where Z is selected from the group consisting of O, S, and NH;
X1 is O;
X2 is C═O;
X3 is O;
or a pharmaceutically acceptable salt thereof;
subject to the proviso that neo-tanshinlactone is excluded therefrom.
|